No profile data available.
Metagenomi, Inc. (MGX) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in EmeryVille, United States, with about 124 full-time employees.
It reported revenue of $52.30 million for fiscal year 2024, up 16.8% from fiscal year 2023, and net income of -$78.06 million. In Q2 2025 (the quarter ended June 30, 2025) revenue was $8.51 million, down 57.5% from a year before. Its market capitalization was $67.21 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of December 4, 2025.
, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases.
Metagenomi reported $52.30 million in revenue for fiscal year 2024, up 16.8% from $44.76 million in fiscal year 2023. In Q2 2025 revenue was $8.51 million.
$67.21 million as of December 4, 2025.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Revium Rx (RVRC), Telomir Pharmaceuticals, Inc. (TELO), XBiotech Inc. (XBIT), Eloxx Pharmaceuticals, Inc. (ELOX).